Jens Bukh

TL;DR: A significant number of southern African Blacks with HCC had a current HCV infection but not a current HBV infection, further suggesting that infection with HCV plays a role, albeit minor, in the development of HCC in this population.

TL;DR: The neutralization synergism obtained when pooling the most potent HMAbs could have significant implications for developing novel strategies to treat and control HCV.

TL;DR: There was a strong cloning selection for defective genomes and that most clones generated initially were incapable of expressing the HCV proteins, finding this has enormous implications for the study of viral heterogeneity.

TL;DR: Of relevance for vaccine evaluation was the titration in chimpanzees of different HCV variants to provide well-characterized challenge pools, and monoclonal virus pools generated from chimpanzees infected with cloned viruses make it possible to examine immunity to HCV without the confounding factor of antigenic diversity of the challenge virus (quasispecies).

TL;DR: Highly efficient HCV full‐length 2b culture systems can be established by using consensus clones with defined mutations, and lead protease and NS5A inhibitors, as well as polymerase inhibitors sofosbuvir, mericitabine, and BI207127, show cross‐activity against full-length 1a, 2a, and 2b viruses, but important sensitivity differences exist at the isolate level.